Catalyst Biosciences Inc (NASDAQ:CBIO) – Analysts at B. Riley upped their FY2017 EPS estimates for shares of Catalyst Biosciences in a report released on Monday. B. Riley analyst G. Zavoico now expects that the biopharmaceutical company will earn ($7.85) per share for the year, up from their previous estimate of ($8.19). B. Riley currently has a “Buy” rating and a $49.00 target price on the stock. B. Riley also issued estimates for Catalyst Biosciences’ Q4 2017 earnings at ($1.41) EPS, Q1 2018 earnings at ($1.30) EPS, Q2 2018 earnings at ($1.32) EPS, Q3 2018 earnings at ($1.42) EPS, Q4 2018 earnings at ($1.50) EPS, FY2018 earnings at ($5.57) EPS, FY2019 earnings at ($7.04) EPS, FY2020 earnings at ($9.13) EPS and FY2021 earnings at ($6.48) EPS.
A number of other research firms have also issued reports on CBIO. Chardan Capital lifted their price objective on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, February 9th. ValuEngine upgraded shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $37.50.
Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in Catalyst Biosciences in the second quarter worth $107,000. Vanguard Group Inc. boosted its holdings in Catalyst Biosciences by 294.1% in the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. Virtu KCG Holdings LLC acquired a new position in Catalyst Biosciences in the second quarter worth $103,000. Dimensional Fund Advisors LP acquired a new position in Catalyst Biosciences in the second quarter worth $372,000. Finally, Geode Capital Management LLC acquired a new position in Catalyst Biosciences in the fourth quarter worth $379,000. Institutional investors and hedge funds own 22.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2018/02/15/b-riley-brokers-raise-earnings-estimates-for-catalyst-biosciences-inc-cbio.html.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.